DIA Biosimilars 2013

Articles Published in 2009

Kendle Reports 78% Drop in Profits, Begins Cost-Saving Efforts

Thursday, May 7, 2009 07:00 AM

Cincinnati-based contract research organization (CRO) Kendle warned investors earlier this month that first quarter 2009 profits would be down, and down they are.

More... »

Cenduit: Now with Patient Reminders

BioClinica Profits Down, Revenues Up Due to Acquisition

Wednesday, May 6, 2009 10:07 AM

BioClinica, the recently renamed and rebranded Bio-Imaging Technologies, reported a 31% drop in profit for the first quarter 2009 compared with the same period last year. Net income decreased from $1.14 million, or $0.09 per diluted share, in 2008, to $786,000, or $0.05 per diluted share, for Q1 2009.

More... »

CRF Health – eCOA Forum

Bio-Imaging to Acquire etrials

Tuesday, May 5, 2009 08:40 AM

Only a week after Bio-Imaging Technologies announced a name change to BioClinica and alluded to future acquisitions, the contract research organization (CRO) announced this morning its intent to acquire troubled eClinical vendor etrials Worldwide.

More... »

CROs See Brighter Future Despite Cancellations

Monday, May 4, 2009 08:00 AM

Contract research organizations (CROs) continue to feel the adverse effects of cancellations and negative foreign exchange, but their most recent earnings reports show some promise.

More... »

CenterWatch Monthly May 2009

Friday, May 1, 2009 11:00 AM

U.S. Sites Rate Novo Nordisk, Novartis and Eisai as Top Sponsors in 2009

More... »

Covance's Q1 Profit Drops, Cuts 2009 Forecast

Thursday, April 30, 2009 07:10 AM

Covance's first quarter profit fell 18%, and the company reduced its 2009 profit guidance. In after hours trading, Covance's shares fell 8.2% to $37.

More... »

Phase Forward Beats Sales, Profit Guidance and Stock Soars 30%

Wednesday, April 29, 2009 09:40 AM

Waltham, Mass.-based eClinical company Phase Forward reported first quarter revenues jumped 28% to $48.8 million, compared with the first quarter of 2008.

More... »

ICON Reports Strong Q1 Earnings, Buys Phase I Unit

Tuesday, April 28, 2009 10:31 AM

Dublin, Ireland-based contract research organization ICON reported strong first quarter net revenues with an increase of 9.2% to $201.3 million compared with the same quarter last year, a 25% hike in profit and hopes to add to that performance by acquiring a 100-bed phase I unit in Omaha, Neb.

More... »

Bio-Imaging Technologies Changes Name to BioClinica, Expects to Acquire More Companies

Tuesday, April 28, 2009 09:05 AM

Now that Newtown, Pa.-based contract research organization Bio-Imaging Technologies has completed its integration of Phoenix Data Systems, which it acquired in March 2008, the company has changed its name to BioClinica. The new name also marks the start of an active acquisition phase for the 450-employee company, which plans to acquire more companies in the clinical research services space.

More... »

Parexel Shares Jump 17% After the Bell on Profit Forecast

Monday, April 27, 2009 07:40 PM

Parexel International, a global contract research organization (CRO), reported an 8% increase in service revenue for its third quarter, flat quarterly profits, but raised its profit outlook for 2009. The CRO’s shares jumped 17.7% in after hours trading to $9.51 a share after closing Monday at $8.08.

More... »

`
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs